Core Laboratories Inc (CLB) financial statements: income statement, balance sheet and cash flow

Core Laboratories Inc's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Core Laboratories Inc reported revenue of $526.5M (+0.5% year on year) and net income of $30.4M (-5.5% year on year).

Income statement

Core Laboratories Inc income statement, fiscal years

Line item	Dec 31, 2025 · FY	Dec 31, 2024 · FY	Dec 31, 2023 · FY
Revenue	$526.5M	$523.8M	$509.8M
Cost of services and product sales exclusive of depreciation expense shown below	$417.6M	$420.5M	$400.0M
General and administrative expense, exclusive of depreciation expense shown below	$45.4M	$39.8M	$40.3M
Depreciation	$14.3M	$14.4M	$15.3M
Amortization	$359.0K	$504.0K	$490.0K
Other (income) expense, net	($7.6M)	($10.0M)	($850.0K)
OPERATING INCOME	$56.5M	$58.6M	$54.6M
Interest expense	$10.6M	$12.4M	$13.4M
Income before income taxes	$45.9M	$46.2M	$41.2M
Income tax expense	$15.5M	$14.0M	($4.2M)
Net income	$30.4M	$32.2M	$37.0M
Net income attributable to non-controlling interest	$722.0K	$753.0K	$350.0K
Net income attributable to Core Laboratories Inc.	$29.7M	$31.4M	$36.7M
Basic earnings per share	$0.65	$0.69	$0.79
Basic earnings per share attributable to Core Laboratories Inc.	$0.64	$0.67	$0.79
Diluted earnings per share	$0.65	$0.67	$0.78
Diluted earnings per share attributable to Core Laboratories Inc.	$0.63	$0.66	$0.77
Basic	46.4M	46.9M	46.7M
Diluted	47.0M	47.7M	47.5M

Core Laboratories Inc income statement, quarters

Line item	Jun 30, 2026 · Q2	Mar 31, 2026 · Q1	Sep 30, 2025 · Q3	Jun 30, 2025 · Q2
Revenue	$124.6M	$121.8M	$134.5M	$130.2M
Cost of services and product sales exclusive of depreciation expense shown below	$101.4M	$102.1M	$104.9M	$103.7M
General and administrative expense, exclusive of depreciation expense shown below	$11.0M	$14.7M	$10.7M	$10.5M
Depreciation	$3.7M	$3.6M	$3.5M	$3.6M
Amortization	$140.0K	$208.0K	$65.0K	$109.0K
Other (income) expense, net	($691.0K)	($645.0K)	($5.6M)	($3.0M)
OPERATING INCOME	$9.2M	$1.9M	$20.9M	$15.3M
Interest expense	$2.8M	$2.9M	$2.6M	$2.7M
Income before income taxes	$6.3M	($1.0M)	$18.3M	$12.6M
Income tax expense	$507.0K	($251.0K)	$3.8M	$1.9M
Net income	$5.8M	($753.0K)	$14.5M	$10.7M
Net income (loss) attributable to non-controlling interest	($158.0K)	$36.0K	$285.0K	$33.0K
Net income attributable to Core Laboratories Inc.	$6.0M	($789.0K)	$14.2M	$10.6M
Basic earnings per share	$0.13	-$0.02	$0.31	$0.23
Basic earnings per share attributable to Core Laboratories Inc.	$0.13	-$0.02	$0.31	$0.23
Diluted earnings per share	$0.12	-$0.02	$0.31	$0.23
Diluted earnings per share attributable to Core Laboratories Inc.	$0.13	-$0.02	$0.30	$0.22
Basic	46.0M	46.1M	46.3M	46.6M
Diluted	46.9M	46.1M	47.1M	47.4M

Balance sheet

Core Laboratories Inc balance sheet, fiscal years

Line item	Dec 31, 2025 · FY	Dec 31, 2024 · FY	Dec 31, 2023 · FY
Cash and cash equivalents	$22.7M	$19.2M	$15.1M
Accounts receivable, net of allowance for credit losses of $6,317 and $3,192 at 2025 and 2024, respectively	$113.5M	$111.8M	$109.4M
Inventories	$54.5M	$59.4M	$71.7M
Prepaid expenses	$9.7M	$10.2M	$8.2M
Income taxes receivable	$7.3M	$15.6M	$13.7M
Other current assets	$6.9M	$10.5M	$5.1M
TOTAL CURRENT ASSETS	$214.7M	$226.6M	$223.1M
PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $320,707 and $314,317 at 2025 and 2024, respectively	$99.4M	$97.1M	$99.6M
RIGHT OF USE ASSETS	$54.3M	$56.5M	$53.8M
INTANGIBLES, net of accumulated amortization and impairment of $19,531 and $19,326 at 2025 and 2024, respectively	$7.1M	$6.4M	$6.9M
GOODWILL	$105.8M	$99.4M	$99.4M
DEFERRED TAX ASSETS, net	$67.4M	$69.6M	$69.2M
OTHER ASSETS	$35.3M	$34.8M	$34.2M
TOTAL ASSETS	$584.0M	$590.4M	$586.4M
Accounts payable	$37.3M	$34.5M	$33.5M
Accrued payroll and related costs	$26.5M	$22.9M	$18.8M
Taxes other than payroll and income	$4.3M	$7.1M	$5.9M
Unearned revenues	$5.6M	$9.3M	$4.8M
Operating lease liabilities	$11.5M	$10.7M	$10.2M
Income taxes payable	$4.3M	$4.9M	$7.3M
Other current liabilities	$16.7M	$8.2M	$7.7M
TOTAL CURRENT LIABILITIES	$106.0M	$97.6M	$88.1M
LONG-TERM DEBT, net	$110.3M	$126.1M	$163.1M
LONG-TERM OPERATING LEASE LIABILITIES	$42.3M	$43.3M	$42.1M
DEFERRED COMPENSATION	$29.4M	$31.1M	$30.5M
DEFERRED TAX LIABILITIES, net	$8.0M	$13.8M	$12.7M
OTHER LONG-TERM LIABILITIES	$15.8M	$20.7M	$20.0M
Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding	0	0	0
Common stock, 200,000,000 shares authorized, $0.01 par value, 46,966,868 issued and 46,095,379 outstanding at 2025; 46,966,868 issued and 46,826,820 outstanding at 2024	470.0K	470.0K	469.0K
Additional paid-in capital	$110.2M	$109.5M	$110.0M
Retained earnings	$172.7M	$150.3M	$120.8M
Accumulated other comprehensive income (loss)	($5.8M)	($5.8M)	($5.0M)
Treasury stock (at cost), 871,489 and 140,048 at 2025 and 2024, respectively	($11.6M)	($2.5M)	($1.4M)
Total Core Laboratories Inc. shareholders' equity	$266.0M	$252.0M	$224.8M
Non-controlling interest	$6.2M	$5.7M	$5.0M
TOTAL EQUITY	$272.2M	$257.7M	$229.8M
TOTAL LIABILITIES AND EQUITY	$584.0M	$590.4M	$586.4M

Core Laboratories Inc balance sheet, quarters

Line item	Jun 30, 2026	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025
Cash and cash equivalents	$22.7M	$22.8M	$25.6M	$31.2M
Accounts receivable, net of allowance for credit losses of $6,504 and $6,317 at 2026 and 2025, respectively	$108.8M	$108.3M	$110.3M	$113.9M
Inventories	$58.0M	$57.8M	$58.2M	$59.8M
Prepaid expenses	$11.0M	$11.4M	$10.1M	$10.5M
Income taxes receivable	$7.3M	$6.9M	$14.7M	$14.0M
Other current assets	$6.6M	$7.2M	$8.0M	$8.2M
TOTAL CURRENT ASSETS	$214.4M	$214.4M	$226.9M	$237.7M
PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $318,900 and $320,707 at 2026 and 2025, respectively	$100.4M	$100.0M	$98.0M	$97.9M
RIGHT OF USE ASSETS	$52.9M	$54.7M	$54.0M	$55.1M
INTANGIBLES, net of accumulated amortization and impairment of $19,879 and $19,531 at 2026 and 2025, respectively	$6.8M	$6.9M	$6.1M	$6.2M
GOODWILL	$105.8M	$105.8M	$100.0M	$100.0M
DEFERRED TAX ASSETS, net	$70.6M	$71.3M	$70.5M	$70.5M
OTHER ASSETS	$36.0M	$34.7M	$35.8M	$34.7M
TOTAL ASSETS	$586.8M	$587.7M	$591.4M	$602.1M
Accounts payable	$40.2M	$40.0M	$36.9M	$41.7M
Accrued payroll and related costs	$21.7M	$22.3M	$23.4M	$25.3M
Taxes other than payroll and income	$3.5M	$4.1M	$3.9M	$3.6M
Unearned revenues	$5.1M	$4.7M	$7.3M	$9.1M
Operating lease liabilities	$11.9M	$12.1M	$11.5M	$11.5M
Income taxes payable	$1.6M	$4.2M	$3.5M	$4.4M
Other current liabilities	$17.0M	$17.4M	$9.3M	$9.1M
TOTAL CURRENT LIABILITIES	$101.0M	$104.7M	$95.7M	$104.8M
LONG-TERM DEBT, net	$113.9M	$114.5M	$114.1M	$124.6M
LONG-TERM OPERATING LEASE LIABILITIES	$39.3M	$41.3M	$41.5M	$42.4M
DEFERRED COMPENSATION	$29.9M	$28.2M	$31.1M	$29.6M
DEFERRED TAX LIABILITIES, net	$7.6M	$8.1M	$10.1M	$11.5M
OTHER LONG-TERM LIABILITIES	$16.3M	$15.9M	$21.4M	$21.9M
Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding	0	0	0	0
Common stock, 200,000,000 shares authorized, $0.01 par value, 46,966,868 issued and 45,884,100 outstanding at 2026; 46,966,868 issued and 46,095,379 outstanding at 2025	470.0K	470.0K	470.0K	470.0K
Additional paid-in capital	$115.5M	$115.2M	$113.9M	$112.8M
Retained earnings	$176.9M	$171.4M	$173.6M	$159.8M
Accumulated other comprehensive income (loss)	($5.7M)	($5.8M)	($6.0M)	($6.0M)
Treasury stock (at cost), 1,082,768 and 871,489 shares at 2026 and 2025, respectively	-14.5M	-12.5M	-10.6M	-5.8M
Total Core Laboratories Inc. shareholders' equity	$272.7M	$268.9M	$271.3M	$261.3M
Non-controlling interest	$6.1M	$6.3M	$6.0M	$6.0M
TOTAL EQUITY	$278.8M	$275.1M	$277.4M	$267.3M
TOTAL LIABILITIES AND EQUITY	$586.8M	$587.7M	$591.4M	$602.1M

Cash flow statement

Core Laboratories Inc cash flow statement, fiscal years

Line item	Dec 31, 2025 · FY	Dec 31, 2024 · FY	Dec 31, 2023 · FY
Net income	$30.4M	$32.2M	$37.0M
Stock-based compensation	$7.1M	$3.8M	$14.0M
Depreciation and amortization	$14.6M	$15.0M	$15.8M
Assets write-down	$34.0K	$1.1M	—
Inventory write-off and obsolescence	$2.3M	$2.9M	—
Net provision for credit losses	$3.4M	$1.2M	$179.0K
Changes in value of life insurance policies	($1.9M)	($2.8M)	($5.0M)
Deferred income taxes	$1.4M	$674.0K	($10.8M)
Insurance recovery on property, plant and equipment	($6.8M)	—	—
Realization of pension obligation	$337.0K	($33.0K)	($892.0K)
Other non-cash items	$682.0K	($1.0M)	$3.3M
Accounts receivable	($5.0M)	($3.6M)	($2.6M)
Inventories	$2.6M	$9.4M	($13.0M)
Prepaid expenses and other current assets	($1.2M)	($5.7M)	$2.0M
Other assets	$28.0K	($289.0K)	$1.5M
Accounts payable	$477.0K	$519.0K	($12.9M)
Accrued expenses	($2.7M)	$2.5M	($375.0K)
Unearned revenues	($3.8M)	$4.6M	($1.2M)
Other liabilities	($5.1M)	$460.0K	($2.2M)
Net cash provided by operating activities	$37.0M	$56.4M	$24.8M
Capital expenditures - operations	($11.2M)	($13.0M)	($10.6M)
Capital expenditures - rebuilding of Aberdeen facility	($3.4M)	—	—
Proceeds from insurance recovery - Aberdeen facility	$10.0M	$2.1M	$0
Proceeds from sale of assets	$3.0M	$1.7M	$485.0K
Patents and other intangibles	($150.0K)	$20.0K	$67.0K
Acquisitions, net of cash acquired	($1.2M)	—	—
Net proceeds on life insurance policies	$778.0K	$2.8M	$3.4M
Net cash used in investing activities	($2.2M)	($6.4M)	($6.7M)
Repayment of long-term debt	($63.0M)	($82.0M)	($211.0M)
Proceeds from long-term debt	$48.0M	$44.0M	$202.0M
Debt issuance costs	($1.7M)	($19.0K)	($1.3M)
Equity related transaction costs	$0	($756.0K)	($4.1M)
Dividends paid	($1.9M)	($1.9M)	($1.9M)
Repurchase of common stock	($12.4M)	($5.3M)	($2.2M)
Other financing activities	($254.0K)	$0	($54.0K)
Net cash used in financing activities	($31.3M)	($46.0M)	($18.4M)
NET CHANGE IN CASH AND CASH EQUIVALENTS	$3.5M	$4.0M	($308.0K)
CASH AND CASH EQUIVALENTS, beginning of year	$19.2M	$15.1M	$15.4M
CASH AND CASH EQUIVALENTS, end of year	$22.7M	$19.2M	$15.1M
Cash payments for interest	$8.2M	$10.9M	$11.2M
Cash payments for income taxes	$18.7M	$17.6M	$16.0M
Restricted shares withheld from employees for settlement of tax liabilities	3.1M	—	—
Business acquisition contingent cash consideration	$4.1M	—	—
Capital expenditures incurred but not paid for as of the end of the year	$1.5M	$1.7M	$963.0K
Equity related transaction costs incurred but not paid for as of the end of the year	$0	$0	$756.0K

Core Laboratories Inc cash flow statement, quarters

Line item	Jun 30, 2026 · YTD	Mar 31, 2026 · Q1	Sep 30, 2025 · YTD	Jun 30, 2025 · YTD
Net income	$5.0M	($753.0K)	$25.3M	$10.7M
Stock-based compensation	$5.9M	$5.0M	$6.0M	$4.7M
Depreciation and amortization	$7.6M	$3.8M	$11.0M	$7.4M
Inventory write-off and obsolescence	$432.0K	$168.0K	$2.4M	$1.6M
Net provision for credit losses	$92.0K	$241.0K	$2.2M	$1.6M
Changes in value of life insurance policies	($1.3M)	$513.0K	($1.9M)	($834.0K)
Deferred income taxes	($1.0K)	($3.7M)	($4.6M)	($3.2M)
Insurance recovery on property, plant and equipment	($175.0K)	—	($6.8M)	($1.6M)
Realization of pension obligation	$94.0K	$47.0K	—	—
Other non-cash items	($113.0K)	($730.0K)	$852.0K	$566.0K
Accounts receivable	$4.6M	$5.0M	($615.0K)	($3.7M)
Inventories	($3.9M)	($3.5M)	($1.3M)	($2.0M)
Prepaid expenses and other current assets	($907.0K)	($1.6M)	($797.0K)	($817.0K)
Other assets	($7.0K)	($7.0K)	($351.0K)	($109.0K)
Accounts payable	$3.3M	$2.8M	$1.3M	$6.6M
Accrued expenses	($8.4M)	($845.0K)	($3.4M)	($886.0K)
Unearned revenues	($476.0K)	($844.0K)	($2.1M)	($218.0K)
Other liabilities	($11.0K)	($1.9M)	$1.8M	$587.0K
Net cash provided by operating activities	$11.8M	$4.0M	$29.1M	$20.6M
Capital expenditures - operations	($8.1M)	($3.4M)	($8.3M)	($6.3M)
Capital expenditures - rebuilding of Aberdeen facility	($2.5M)	($1.4M)	($2.7M)	($1.6M)
Proceeds from insurance recovery - Aberdeen facility	$0	$0	$10.0M	$4.7M
Acquisitions, net of cash acquired	$0	—	($617.0K)	($617.0K)
Proceeds from sale of assets	$3.1M	$1.5M	$2.3M	$2.2M
Patents and other intangibles	$11.0K	$9.0K	($2.0K)	$0
Net proceeds on life insurance policies	$252.0K	—	$778.0K	$778.0K
Net cash used in investing activities	($7.3M)	($3.4M)	$1.5M	($872.0K)
Repayment of long-term debt	($77.6M)	($62.0M)	($47.0M)	($27.0M)
Proceeds from long-term debt	$81.0M	$66.0M	$36.0M	$25.0M
Dividends paid	($920.0K)	($460.0K)	($1.4M)	($938.0K)
Repurchase of common stock	($6.7M)	($4.0M)	($9.8M)	($4.8M)
Other financing activities	($186.0K)	$0	($255.0K)	$19.0K
Net cash used in financing activities	($4.4M)	($457.0K)	($24.1M)	($7.7M)
NET CHANGE IN CASH AND CASH EQUIVALENTS	$33.0K	$117.0K	$6.5M	$12.0M
CASH AND CASH EQUIVALENTS, beginning of period	$22.7M	$22.7M	$19.2M	$19.2M
CASH AND CASH EQUIVALENTS, end of period	$22.7M	$22.8M	$25.6M	$31.2M
Cash payments for interest	$4.3M	$2.9M	$6.6M	$4.1M
Cash payments (net of refunds) for income taxes	$6.5M	$3.0M	$9.5M	$4.9M
Capital expenditures incurred but not paid for as of the end of the period	$1.3M	$1.5M	$1.0M	$819.0K

Core Laboratories Inc score and earnings-call analysis · All covered companies

Figures as reported in SEC filings. General information, not investment advice.